Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Male/Female with histologically confirmed GCT with review by the Department of Pathology at this center.~* Patients with advanced GCT, including patients with:~measurable or evaluable disease,~* patients with only elevated serum tumor markers (AFP and/or HCG), or~* patients with known residual disease after postchemotherapy surgery. Eligible patients must have established clinical resistance to cisplatin by their failure to achieve a durable CR to a cisplatin-based regimen.~* Prior treatment limited to ≤ 6 prior cycles (≤ four cycles preferred) of cisplatin. (GROUP A)~* Prior therapy \> 6 cycles of cisplatin. (GROUP B)~* Therapy must have been discontinued at least 3 weeks before entry onto protocol.~* Patients must have one or more unfavorable prognostic factors for achieving a CR to cisplatin-based salvage therapy. These are:~* Extragonadal primary site.~* Testis/ovarian primary site with the best response of an IR to first-line therapy, or a partial response with normal tumor markers of six months or less in duration.~* Prior treatment with ifosfamide-containing therapy~* General medical condition sufficient to allow for general anesthesia at the time of pheresis catheter placement.~* Patients must have negative serology for Human Immunodeficiency Virus.~* Laboratory criteria for protocol entry:~WBC ≥ 3000/ul Platelets 3 100,000/ul Cr Clearance \> 50 cc/min\*~\* (unless renal dysfunction is due to tumor obstructing the ureters in which case eligibility will be determined by the Principal Investigator).~* Age ≥ 15 years.~* Signed informed consent.~Exclusion Criteria:~* Presence of active infection~* Concurrent treatment with chemotherapy or~* Inability to comply with the treatment protocol or to undergo the specified follow-up tests for safety or effectiveness.~* Prior high-dose therapy with AuBMT.~* Patients must have recovered from recent surgery.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy administered with G-CSF and PBSC support (Type: EXPERIMENTAL): The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.

Based on this trial design, predict the completion outcome and termination type (if applicable).